NCT05135312

Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging

Monitoring Nail Changes in Patients With Psoriatic Disease Treated With Etanercept Using Non- Invasive Optical Coherence Tomography

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: OptiSkin Medical · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

OptiSkin is now enrolling a new study to monitor nail changes in patients with nail psoriasis treated with Enbrel® (etanercept) with optical coherence tomography (OCT).

Detailed description

Psoriasis often affects the fingernails, making them yellow, brittle, painful and prone to infections. These symptoms can be difficult to manage, so OptiSkin is now enrolling a new study to monitor nail changes in patients with nail psoriasis treated with Enbrel® (etanercept) with optical coherence tomography (OCT). OCT is being studied as a way to better diagnosis psoriatic nail disease, monitor response to therapy, and identify changes even before they become apparent, potentially leading to earlier treatment or prevention of future psoriatic arthritis. Study-related care and medication are provided at no cost, and reimbursement for reasonable local transportation may be available to qualified individuals.

Conditions

• Psoriasis
• Psoriatic Arthritis
• Psoriatic Nail

Interventions

Type	Name	Description
DRUG	Etanercept	TNF-alpha inhibitors improve nail psoriasis.
DEVICE	OCT	Optical Coherence Tomography is a noninvasive imaging device that can be used to monitor nail disease severity.

Timeline

• Start date: 2021-08-09
• Primary completion: 2022-08-08
• Completion: 2022-08-08
• First posted: 2021-11-26
• Last updated: 2022-01-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study
• FDA-regulated device study